Theracurmin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest

Kang,Minyong; Ho,Jin-Nyoung; Kook,Ha Rim; Lee,Sangchul; Oh,Jong Jin; Hong,Sung Kyu; Lee,Sang Eun; Byun,Seok-Soo

doi:10.3892/or.2015.4537

Theracurmin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest

Authors:
- Minyong Kang
- Jin-Nyoung Ho
- Ha Rim Kook
- Sangchul Lee
- Jong Jin Oh
- Sung Kyu Hong
- Sang Eun Lee
- Seok-Soo Byun
View Affiliations

Affiliations: Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea
Published online on: December 29, 2015 https://doi.org/10.3892/or.2015.4537
Pages: 1463-1472

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we aimed to investigate the anticancer properties of Theracurmin®, a novel form of the yellow curry pigment curcumin, as well as explore the molecular mechanisms of the potential anticancer effects of Theracurmin® on human prostate cancer and bladder cancer cells in vitro. The proliferation of cancer cells was examined by using the Cell Counting Kit-8. The clonogenic growth potential was determined by clonogenic assay. Cell cycle distribution was evaluated by flow cytometry using propidium iodide staining. Western blot analysis was applied to explore the expression patterns of molecules associated with apoptotic cell death and cell cycle checkpoint. We noted that Theracurmin® and curcumin exhibited similar anticancer effects in both androgen-dependent and -independent human prostate cancer cells in a dose- and time-dependent manner. These agents reduced cell viability and clonogenic growth potential by inducing apoptosis and cell cycle disturbance in human prostate cancer cells. Theracurmin® and curcumin also exerted marked anticancer effects on human bladder cancer cells, even in cisplatin-resistant T24R2 cells, in a dose- and time-dependent manner. Moreover, Theracurmin® and curcumin treatment decreased cell viability and clonogenicity via induction of apoptotic cell death and cell cycle dysregulation in human bladder cancer cells. In conclusion, our study suggests that Theracurmin® has potential as an anticancer agent in complementary and alternative medicine for these urological cancers.

View Figures

View References

1	Rossi E, Vita A, Baccetti S, Di Stefano M, Voller F and Zanobini A: Complementary and alternative medicine for cancer patients: Results of the EPAAC survey on integrative oncology centres in Europe. Support Care Cancer. 23:1795–1806. 2015. View Article : Google Scholar
2	Ventola CL: Current issues regarding complementary and alternative medicine (CAM) in the United States: Part 1: The widespread use of CAM and the need for better-informed health care professionals to provide patient counseling. P T. 35:461–468. 2010.PubMed/NCBI
3	Tuorkey MJ: Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci. 6:139–146. 2014. View Article : Google Scholar
4	Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 223:181–190. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kamat AM, Sethi G and Aggarwal BB: Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther. 6:1022–1030. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 67:3853–3861. 2007. View Article : Google Scholar : PubMed/NCBI
7	Tian F, Fan T, Zhang Y, Jiang Y and Zhang X: Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 44:847–855. 2012. View Article : Google Scholar
8	Li L, Braiteh FS and Kurzrock R: Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 104:1322–1331. 2005. View Article : Google Scholar : PubMed/NCBI
9	Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, et al: Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 34:660–665. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bisht S, Feldmann G, Soni S, Ravi R, Karikar C and Maitra A and Maitra A: Polymeric nanoparticle-encapsulated curcumin ('nanocurcumin'): A novel strategy for human cancer therapy. J Nanobiotechnology. 5:32007. View Article : Google Scholar
11	Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR and Aggarwal BB: Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 79:330–338. 2010. View Article : Google Scholar
12	Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee SE and Yeon JS: Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J Urol. 193:1016–1022. 2015. View Article : Google Scholar
13	Philippou Y, Hadjipavlou M, Khan S and Rane A: Complementary and alternative medicine (CAM) in prostate and bladder cancer. BJU Int. 112:1073–1079. 2013. View Article : Google Scholar : PubMed/NCBI
14	Klempner SJ and Bubley G: Complementary and alternative medicines in prostate cancer: From bench to bedside? Oncologist. 17:830–837. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kamat AM, Tharakan ST, Sung B and Aggarwal BB: Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res. 69:8958–8966. 2009. View Article : Google Scholar : PubMed/NCBI
16	Tian B, Wang Z, Zhao Y, Wang D, Li Y, Ma L, Li X, Li J, Xiao N, Tian J, et al: Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. 264:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
17	Lao CD, Ruffin MT IV, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL and Brenner DE: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 6:102006. View Article : Google Scholar : PubMed/NCBI
18	Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H and Chiba T: Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 69:65–70. 2012. View Article : Google Scholar
19	Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, et al: A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 71:1521–1530. 2013. View Article : Google Scholar : PubMed/NCBI
20	Morimoto T, Sunagawa Y, Katanasaka Y, Hirano S, Namiki M, Watanabe Y, Suzuki H, Doi O, Suzuki K, Yamauchi M, et al: Drinkable preparation of Theracurmin exhibits high absorption efficiency - a single-dose, double-blind, 4-way crossover study. Biol Pharm Bull. 36:1708–1714. 2013. View Article : Google Scholar
21	Milano F, Mari L, van de Luijtgaarden W, Parikh K, Calpe S and Krishnadath KK: Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response. Front Oncol. 3:1372013. View Article : Google Scholar : PubMed/NCBI
22	Park C, Kim GY, Kim GD, Choi BT, Park YM and Choi YH: Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncol Rep. 15:1225–1231. 2006.PubMed/NCBI
23	Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S and Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 73:1024–1032. 2007. View Article : Google Scholar : PubMed/NCBI
24	Nowsheen S and Yang ES: The intersection between DNA damage response and cell death pathways. Exp Oncol. 34:243–254. 2012.PubMed/NCBI
25	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
26	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
28	He M, Li Y, Zhang L, Li L, Shen Y, Lin L, Zheng W, Chen L, Bian X, Ng HK, et al: Curcumin suppresses cell proliferation through inhibition of the Wnt/β-catenin signaling pathway in medulloblastoma. Oncol Rep. 32:173–180. 2014.PubMed/NCBI
29	Lu Y, Wei C and Xi Z: Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway. In Vitro Cell Dev Biol Anim. 50:840–850. 2014. View Article : Google Scholar : PubMed/NCBI
30	Park CH, Hahm ER, Park S, Kim HK and Yang CH: The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett. 579:2965–2971. 2005. View Article : Google Scholar : PubMed/NCBI
31	Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB and Kumar NB: Curcumin: A novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 21:407–412. 2012. View Article : Google Scholar :
32	Xu X, Qin J and Liu W: Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway. Gene. 546:226–232. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhou H, Beevers CS and Huang S: The targets of curcumin. Curr Drug Targets. 12:332–347. 2011. View Article : Google Scholar :